Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Shao, Qingmiao; Meng, Lei; Lee, Sharen; Tse, Gary; Gong, Mengqi; Zhang, Zhiwei; Zhao, Jichao; Zhao, Yungang; Li, Guangping; Liu, Tong

doi:10.1186/s12933-019-0964-4

Public

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Published in Cardiovascular Diabetology • Nov 28, 2019

Authors:

Qingmiao Shao

Lei Meng

Sharen Lee

Abstract

BACKGROUND: Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their cardioprotective effects have been reported but whether they prevent AF in T2DM...

Subject

Empagliflozin

TFAM

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!